Picture of Abeona Therapeutics logo

ABEO — Abeona Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Abeona Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

* Abeona Therapeutics Inc  ABEO.OQ   ABEO.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * The Cleveland Ohio-based  company is expected to report
revenue
of $166.67 thousand, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Abeona Therapeutics Inc
is for
a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Abeona
Therapeutics Inc is $17.00​, above​ its last closing price
of $4.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.47      -0.77     Missed  -63.8
 Sep. 30 2023  -0.53       -0.53      -0.48     Beat    8.9
 Jun. 30 2023  -0.71       -0.68      -0.92     Missed  -35.3​
 Mar. 31 2023  -0.62       -0.58      -0.54     Beat    6.9
 ​​Dec.                    -0.75      1.53      Beat    304
 31 2022                                                
 Sep. 30 2022  -1.75       -1.75      -1.48     Beat    15.3​
 Jun. 30 2022  -1.94       -1.87      -2.08     Missed  -10.9
 Mar. 31 2022  -2.00       -2.37      -3.50     Missed  -47.4
 This summary was machine generated May 7 at 12:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Abeona Therapeutics

See all news